Candidate Clinton calls for $2B in annual Alzheimer's R&D support

Alzheimer's drug research has been one of the toughest fields in R&D, claiming a host of clinical trial failures. And now it's becoming an issue in the race for the White House. Democratic candidate Hillary Clinton wants to spend $2 billion a year on R&D activities in Alzheimer's over the next 10 years as millions of patients and their families deal with the memory-stealing malady. That's more than double the current spending. Story (sub. req.)

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.